prodchem
Aug 28, 2026
A major biotech acquisition can require months of financial, scientific, legal and operational investigation. Eli Lilly's long-standing role as a founding investor and Series C participant in Ajax created an established relationship that significantly simplified the due diligence logistics typically associated with a major biotech acquisition.
For investors and corporate development teams, the significance extends beyond one transaction. Existing investor relationships can provide institutional knowledge, established communication channels and greater familiarity with a target's business, potentially reducing duplication during a complex acquisition process.
For pharmaceutical procurement professionals and industry suppliers, the lesson is also relevant. When ownership changes hands, an established relationship can help accelerate the transition from transaction planning to operational integration.
Biotech companies present unusual due diligence requirements because their value often depends on assets that do not appear straightforwardly on a conventional balance sheet. Drug candidates, intellectual property, clinical programs, regulatory pathways and scientific teams can all influence the investment case.
A buyer therefore needs to investigate several dimensions simultaneously:
Scientific assets: Teams assess the quality, differentiation and development potential of the target's research programs.
Intellectual property: Patent ownership, licensing arrangements and potential restrictions can materially affect an acquisition.
Clinical development: Buyers examine trial progress, development plans and the evidence supporting future programs.
Regulatory position: Existing approvals, filings and regulatory obligations require careful review.
Financial condition: Revenue, cash requirements, liabilities and projected development costs shape the transaction economics.
Operations: Manufacturing, research infrastructure, suppliers and technical capabilities require separate assessment.
An investor that has already participated in the company's financing may possess useful background knowledge across several of these areas.
Lilly's relationship with Ajax gave the pharmaceutical company a degree of familiarity that a completely external buyer would not normally have.
As a founding investor and Series C participant, Lilly had an established connection with Ajax before the acquisition process. That history can create a more efficient information flow because the parties already understand key elements of the company's development, governance and investment history.
The advantage does not eliminate diligence. Instead, it can reduce the amount of time spent reconstructing information that an existing investor has already encountered through earlier financing and engagement.
This distinction matters for transaction teams. Familiarity can accelerate diligence without replacing it.
The greatest benefit of a long-standing investor relationship often comes from reducing information friction.
A new buyer may need to build its understanding of a target from the beginning. An existing investor may already understand the company's financing history, major stakeholders and strategic direction.
That can simplify early-stage transaction work in several ways:
Historical context: Previous investment participation provides a foundation for understanding how the company developed.
Established contacts: Existing relationships can make communication between corporate development, management and investment teams more direct.
Document familiarity: Prior financing activity may provide access to documentation and historical transaction records.
Strategic understanding: The investor may already understand why particular assets or programs matter.
Faster issue identification: Familiarity can help transaction teams focus earlier on unresolved risks rather than spending time identifying basic background information.
These efficiencies become increasingly valuable when a transaction involves sensitive scientific information and multiple specialist advisers.
Even with an existing investor relationship, pharmaceutical acquisitions require detailed cross-functional analysis.
A corporate development team may coordinate specialists covering science, regulatory affairs, intellectual property, finance, tax, legal matters and commercial strategy. Each function examines the target from a different perspective.
The process can become especially complex when a target owns or develops multiple programs at different stages.
Scientific diligence may focus on research validity and development prospects. Legal teams may concentrate on ownership rights and contractual obligations, while finance teams assess the capital required to advance programs after closing.
An established relationship helps most when these teams can access relevant information efficiently.
A virtual data room remains an important tool for organizing acquisition information, but efficient diligence depends on more than uploading documents.
Teams need to know which documents matter, which information requires additional investigation and where gaps remain. Historical familiarity can help an existing investor navigate the information environment more efficiently.
The same principle applies to management discussions.
Direct conversations with executives and technical personnel can provide context that documents cannot fully capture. A long-standing investor relationship may make these conversations more productive because participants already share some institutional history.
This can shorten the path from information gathering to decision-making.
Biotech acquisitions carry several forms of uncertainty. A promising scientific program can face development setbacks, regulatory challenges or commercial competition even when initial data looks attractive.
An existing investor may have observed the company's decision-making over several financing stages. That history can provide additional context when evaluating management quality, strategic priorities and the evolution of the company's research programs.
However, efficient diligence still requires fresh analysis.
A buyer must evaluate the target based on its current circumstances, not simply rely on previous investment experience. Scientific programs may have changed, market conditions may have shifted and new liabilities may have emerged since the original investment.
The strongest advantage comes from better starting knowledge combined with current diligence.
A major biotech acquisition can require months of financial, scientific, legal and operational investigation. Eli Lilly's long-standing role as a founding investor and Series C participant in Ajax created an established relationship that significantly simplified the due diligence logistics typically associated with a major biotech acquisition.
For investors and corporate development teams, the significance extends beyond one transaction. Existing investor relationships can provide institutional knowledge, established communication channels and greater familiarity with a target's business, potentially reducing duplication during a complex acquisition process.
For pharmaceutical procurement professionals and industry suppliers, the lesson is also relevant. When ownership changes hands, an established relationship can help accelerate the transition from transaction planning to operational integration.
Biotech companies present unusual due diligence requirements because their value often depends on assets that do not appear straightforwardly on a conventional balance sheet. Drug candidates, intellectual property, clinical programs, regulatory pathways and scientific teams can all influence the investment case.
A buyer therefore needs to investigate several dimensions simultaneously:
Scientific assets: Teams assess the quality, differentiation and development potential of the target's research programs.
Intellectual property: Patent ownership, licensing arrangements and potential restrictions can materially affect an acquisition.
Clinical development: Buyers examine trial progress, development plans and the evidence supporting future programs.
Regulatory position: Existing approvals, filings and regulatory obligations require careful review.
Financial condition: Revenue, cash requirements, liabilities and projected development costs shape the transaction economics.
Operations: Manufacturing, research infrastructure, suppliers and technical capabilities require separate assessment.
An investor that has already participated in the company's financing may possess useful background knowledge across several of these areas.
Lilly's relationship with Ajax gave the pharmaceutical company a degree of familiarity that a completely external buyer would not normally have.
As a founding investor and Series C participant, Lilly had an established connection with Ajax before the acquisition process. That history can create a more efficient information flow because the parties already understand key elements of the company's development, governance and investment history.
The advantage does not eliminate diligence. Instead, it can reduce the amount of time spent reconstructing information that an existing investor has already encountered through earlier financing and engagement.
This distinction matters for transaction teams. Familiarity can accelerate diligence without replacing it.
The greatest benefit of a long-standing investor relationship often comes from reducing information friction.
A new buyer may need to build its understanding of a target from the beginning. An existing investor may already understand the company's financing history, major stakeholders and strategic direction.
That can simplify early-stage transaction work in several ways:
Historical context: Previous investment participation provides a foundation for understanding how the company developed.
Established contacts: Existing relationships can make communication between corporate development, management and investment teams more direct.
Document familiarity: Prior financing activity may provide access to documentation and historical transaction records.
Strategic understanding: The investor may already understand why particular assets or programs matter.
Faster issue identification: Familiarity can help transaction teams focus earlier on unresolved risks rather than spending time identifying basic background information.
These efficiencies become increasingly valuable when a transaction involves sensitive scientific information and multiple specialist advisers.
Even with an existing investor relationship, pharmaceutical acquisitions require detailed cross-functional analysis.
A corporate development team may coordinate specialists covering science, regulatory affairs, intellectual property, finance, tax, legal matters and commercial strategy. Each function examines the target from a different perspective.
The process can become especially complex when a target owns or develops multiple programs at different stages.
Scientific diligence may focus on research validity and development prospects. Legal teams may concentrate on ownership rights and contractual obligations, while finance teams assess the capital required to advance programs after closing.
An established relationship helps most when these teams can access relevant information efficiently.
A virtual data room remains an important tool for organizing acquisition information, but efficient diligence depends on more than uploading documents.
Teams need to know which documents matter, which information requires additional investigation and where gaps remain. Historical familiarity can help an existing investor navigate the information environment more efficiently.
The same principle applies to management discussions.
Direct conversations with executives and technical personnel can provide context that documents cannot fully capture. A long-standing investor relationship may make these conversations more productive because participants already share some institutional history.
This can shorten the path from information gathering to decision-making.
Biotech acquisitions carry several forms of uncertainty. A promising scientific program can face development setbacks, regulatory challenges or commercial competition even when initial data looks attractive.
An existing investor may have observed the company's decision-making over several financing stages. That history can provide additional context when evaluating management quality, strategic priorities and the evolution of the company's research programs.
However, efficient diligence still requires fresh analysis.
A buyer must evaluate the target based on its current circumstances, not simply rely on previous investment experience. Scientific programs may have changed, market conditions may have shifted and new liabilities may have emerged since the original investment.
The strongest advantage comes from better starting knowledge combined with current diligence.
Featured Product
Found this useful?
Continue Reading
Clariant's CFO leadership transition, from interim coverage to permanent appointment, highlights the governance and disclosure processes required during major executive changes. The transition also offers lessons for procurement teams and chemical suppliers monitoring leadership shifts.
Product stewardship in 2026 hinges on substituting persistent bioaccumulative and toxic compounds. This analysis quantifies the reformulation cost curve and timeline pressure from REACH-adjacent restrictions.
Regeneron's successful navigation of the FDA's newer national priority voucher program for Otarmeni provides a working precedent for the developing regulatory pathway. The approval also offers lessons for pharmaceutical companies planning manufacturing, procurement and commercial launch activities around accelerated review.
